Patents by Inventor Steve Roczniak
Steve Roczniak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110183920Abstract: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.Type: ApplicationFiled: August 25, 2010Publication date: July 28, 2011Applicant: AEROVANCE, INC.Inventors: Clark Pan, Steve Roczniak, Jeffrey Michael Greve, Stephanie L. Yung, Malinda Longphre, Teresa Mo-Fun Wong, Adrian Tomkinson, David Boisvert, Elise Burmeister-Getz, Kathy Delaria
-
Patent number: 7785580Abstract: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.Type: GrantFiled: November 14, 2007Date of Patent: August 31, 2010Assignee: Aerovance, Inc.Inventors: Clark Pan, Steve Roczniak, Jeffrey Michael Greve, Stephanie L. Yung, Malinda Longphre, Teresa Mo-Fun Wong, Adrian Tomkinson, David Boisvert, Elise Burmeister-Getz, Kathy Delaria
-
Publication number: 20090010874Abstract: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.Type: ApplicationFiled: November 14, 2007Publication date: January 8, 2009Applicant: AEROVANCE, INC.Inventors: Clark Pan, Steve Roczniak, Jeffrey Michael Greve, Stephanie L. Yung, Malinda Longphre, Teresa Mo-Fun Wong, Adrian Tomkinson
-
Patent number: 7404957Abstract: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.Type: GrantFiled: April 8, 2004Date of Patent: July 29, 2008Assignee: Aerovance, Inc.Inventors: Clark Pan, Steve Roczniak, Jeffrey Michael Greve, Stephanie L. Yung, Malinda Longphre, Teresa Mo-fun Wong, Adrian Tomkinson
-
Publication number: 20050203009Abstract: The disclosed invention relates to selective VPAC1 antagonists, related formulations, dosages and methods of use. The selective VPAC1 antagonists of the invention comprise a vasoactive intestinal peptide component and a growth hormone releasing hormone component capable of selectively binding to and antagonizing the VPAC1 receptor at significantly lower concentrations than those concentrations at which it binds to and antagonizes the VPAC2 receptor.Type: ApplicationFiled: March 12, 2004Publication date: September 15, 2005Inventors: Clark Pan, Steve Roczniak
-
Publication number: 20050059590Abstract: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.Type: ApplicationFiled: April 8, 2004Publication date: March 17, 2005Applicant: Bayer Pharmaceuticals CorporationInventors: Clark Pan, Steve Roczniak, Jeffrey Greve, Stephanie Yung, Malinda Longphre, Teresa Wong, Adrian Tomkinson
-
Patent number: 6689582Abstract: BTL.010 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase and proteinase 3 than towards trypsin-like proteinases. BTL.010, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.Type: GrantFiled: May 12, 2000Date of Patent: February 10, 2004Assignee: Bayer Pharmaceuticals CorporationInventors: Christopher Davies, Dadong Chen, Steve Roczniak
-
Publication number: 20040023864Abstract: Ryk protein was found to have a novel activity in regulating angiogenesis. New variant Ryk proteins were constructed that were useful in modulating the capillary forming activity of endothelial cells. Variant Ryk proteins, may be employed as therpeutics in diseases such as cancer, wound healing, diabetic retinopathies, macular degeneration, and cardiovascular diseases, and other diseases or clinical conditions where angiogenesis is relevant to the causation or treatment of the disease.Type: ApplicationFiled: June 17, 2003Publication date: February 5, 2004Inventors: Steve Roczniak, Nathalie A. Dubois-Stringfellow, Alya Zolotorev
-
Patent number: 6294648Abstract: BTL.009 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase, and chymotrypsin than towards trypsin-like proteinases. BTL.009, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.Type: GrantFiled: July 20, 1999Date of Patent: September 25, 2001Assignee: Bayer CorporationInventors: Kathy Delaria, Steve Roczniak, Christopher Davies
-
Patent number: 6180607Abstract: BTL.010 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase-, and proteinase 3, than towards trypsin-like proteinases. BTL.010, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.Type: GrantFiled: August 5, 1999Date of Patent: January 30, 2001Inventors: Christopher Davies, Dadong Chen, Steve Roczniak